XML 23 R11.htm IDEA: XBRL DOCUMENT
v3.22.4

Fair Value Measurements | 12 Months Ended
--- | ---
Dec. 31, 2022
Fair Value Disclosures [Abstract] |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration related to the acquisitions of Sividon Diagnostics GmbH ("Sividon") and Gateway, the Company reassesses the fair value of each expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected contingent consideration liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement periods of approximately 12.5 and 2.3 years for Sividon and Gateway, respectively, utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the contingent consideration itself, the related projections, and the overall business. The contingent consideration liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Consolidated Balance Sheets. Changes to contingent consideration liabilities are reflected in Selling, general, and administrative expense in the Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements. The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:
(in millions) | Level 1 |  | Level 2 |  | Level 3 |  | Total
December 31, 2022 |  |  |  |  |  |  |
Money market funds (a) | $ | 3.3 |  |  | $ | — |  |  | $ | — |  |  | $ | 3.3 |
Corporate bonds and notes | — |  |  | 65.1 |  |  | — |  |  | 65.1 |
Municipal bonds | — |  |  | 16.0 |  |  | — |  |  | 16.0 |
Federal agency issues | — |  |  | 20.0 |  |  | — |  |  | 20.0 |
U.S. government securities | — |  |  | 11.7 |  |  | — |  |  | 11.7 |
Contingent consideration | — |  |  | — |  |  | (6.8) |  |  | (6.8) |
Total | $ | 3.3 |  |  | $ | 112.8 |  |  | $ | (6.8) |  |  | $ | 109.3 |
(in millions) | Level 1 |  | Level 2 |  | Level 3 |  | Total
December 31, 2021 |  |  |  |  |  |  |
Money market funds (a) | $ | 63.2 |  |  | $ | — |  |  | $ | — |  |  | $ | 63.2 |
Corporate bonds and notes | — |  |  | 105.6 |  |  | — |  |  | 105.6 |
Municipal bonds | — |  |  | 16.1 |  |  | — |  |  | 16.1 |
Federal agency issues | — |  |  | 6.8 |  |  | — |  |  | 6.8 |
U.S. government securities | — |  |  | 11.9 |  |  | — |  |  | 11.9 |
Contingent consideration | — |  |  | — |  |  | (8.6) |  |  | (8.6) |
Total | $ | 63.2 |  |  | $ | 140.4 |  |  | $ | (8.6) |  |  | $ | 195.0 |
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest. The following table reconciles the change in the fair value of the contingent consideration during the periods presented:
(in millions) | Years Ended December 31, |  | Transition Period Ended December 31, |  | Year Ended June 30,
| 2022 |  | 2021 |  | 2020 |  | 2020
Carrying amount at beginning of period | $ | 8.6 |  |  | $ | 10.9 |  |  | $ | 6.8 |  |  | $ | 13.8 |
Payment of contingent consideration | (3.0) |  |  | (3.3) |  |  | (0.1) |  |  | (3.9) |
Consideration recognized at acquisition | 2.1 |  |  | — |  |  | — |  |  | — |
Change in fair value recognized in the statement of operations | (0.4) |  |  | 1.8 |  |  | 3.5 |  |  | (2.8) |
Translation adjustments recognized in other comprehensive income (loss) | (0.5) |  |  | (0.8) |  |  | 0.7 |  |  | (0.3) |
Carrying amount at end of period | $ | 6.8 |  |  | $ | 8.6 |  |  | $ | 10.9 |  |  | $ | 6.8 |

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration